Hepion Pharmaceuticals (STU:3360) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3360 Hepion Pharmaceuticals Inc STU:3360
33 GF Score
Price €466.00
! 2 Warning Signs
View Full Analysis

What is Hepion Pharmaceuticals Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:3360
33GF Score
Hepion Pharmaceuticals Inc STU:3360
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hepion Pharmaceuticals Business Description

Other Exchanges HEPA:USA
Address 55 Madison Avenue, Suite 400- PMB 4362, Morristown, NJ, USA, 07960
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses on the development of drug therapy for the treatment of chronic liver diseases. The company is pioneering early cancer detection solutions with a novel liquid biopsy. diagnostics. The company's mission is to redefine the early detection of hepatocellular carcinoma, moving from missed diagnoses to timely, precise intervention. It's focused on delivering non-invasive, clinically grounded liquid biopsy solutions for patients at the highest risk, particularly those living with cirrhosis.
33GF Score

Get the complete analysis for STU:3360

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€466.00
Price